Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SDGR
SELLSchrödinger, Inc. · Healthcare · United States · $1.1B · Avg Vol: $22M/d
COMPANY DESCRIPTION
Schrödinger, Inc. offers a physics-based computational platform that accelerates drug discovery and materials science research by enabling the prediction of molecular properties with high accuracy. The company's competitive advantage lies in its proprietary, industry-leading simulation software and deep scientific expertise, establishing it as a critical technology partner for pharmaceutical and biotech innovators.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 181.0M | 216.7M | 207.5M | 255.9M | 12.2% | 259.0M | 240.3M | 266.7M | 2.1% |
| EPS | -2.10 | 0.57 | -2.57 | -1.41 | — | -0.73 | -1.83 | -1.35 | — |
| Shares | 71.3M | 72.1M | 72.9M | 73.7M | +3.3% | 65.6M | — | — | — |
| Debt | 116.5M | 127.9M | 117.8M | 109.2M | -2.1% | 108.0M | — | — | — |
| Equity | 447.9M | 548.6M | 421.4M | 364.1M | -6.7% | — | — | — | — |
| Op CF | -119.7M | -136.7M | -157.4M | 13.9M | — | -126.9M | — | — | — |
| Inv CF | 90.0M | 193.0M | 148.8M | 57.9M | — | — | — | — | — |
| Fin CF | 2.1M | 9.0M | 10.1M | 2.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SDGR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SDGR | Schrödinger, Inc.(you) | $1.1B | 34 | SELL |
| CERT | Certara, Inc. | $1.2B | 46 | HOLD |
| HTFL | Heartflow, Inc. | $2.1B | 28 | SELL |
| EVH | Evolent Health, Inc. | $475M | 37 | HOLD |
| PHR | Phreesia, Inc. | $632M | 47 | HOLD |
| TDOC | Teladoc Health, Inc. | $1.6B | 56 | HOLD |
| WEAV | Weave Communications, Inc. | $491M | 47 | HOLD |
| CARL | Carlsmed, Inc. | $294M | 38 | HOLD |
| TALK | Talkspace, Inc. | $873M | 63 | HOLD |
| OMDA | Omada Health, Inc. | $1.2B | 67 | BUY |
Peer medians: ROE -25.8% · P/E 30.1x · Gross margin 55.7%